Holen Sie sich die Stockscreener-App
14.43
3.08%
-0.47
Schlusskurs vom Vortag:
$14.90
Offen:
$15.03
24-Stunden-Volumen:
497.22K
Relative Volume:
0.47
Marktkapitalisierung:
$1.02B
Einnahmen:
$114.04M
Nettoeinkommen (Verlust:
$-330.15M
KGV:
-3.0507
EPS:
-4.73
Netto-Cashflow:
$-274.85M
1W Leistung:
-2.03%
1M Leistung:
+8.99%
6M Leistung:
+63.54%
1J Leistung:
+55.45%
1-Tages-Spanne:
$14.38
$15.14
1-Wochen-Bereich:
$14.12
$15.16
52-Wochen-Spanne:
$2.21
$16.27
Phathom Pharmaceuticals Inc Stock (PHAT) Company Profile
Firmenname
Phathom Pharmaceuticals Inc
Sektor
Branche
Telefon
(877) 742-8466
Adresse
100 CAMPUS DRIVE,, FLORHAM PARK, NJ
Vergleichen Sie PHAT mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PHAT
Phathom Pharmaceuticals Inc
|
14.40 | 1.06B | 114.04M | -330.15M | -274.85M | -4.73 |
|
VRTX
Vertex Pharmaceuticals Inc
|
438.54 | 112.15B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
700.32 | 73.91B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
417.88 | 56.81B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
892.74 | 55.46B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
193.73 | 41.92B | 447.02M | -1.18B | -906.14M | -6.1812 |
Phathom Pharmaceuticals Inc Stock (PHAT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-02-14 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-05-03 | Eingeleitet | Stifel | Buy |
| 2024-01-05 | Bestätigt | Needham | Buy |
| 2023-08-09 | Eingeleitet | H.C. Wainwright | Buy |
| 2023-05-11 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2023-03-13 | Eingeleitet | Craig Hallum | Buy |
| 2022-10-21 | Eingeleitet | Jefferies | Buy |
| 2022-05-06 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2021-05-12 | Hochstufung | Goldman | Sell → Neutral |
| 2021-02-17 | Eingeleitet | BMO Capital Markets | Outperform |
| 2021-02-02 | Eingeleitet | Guggenheim | Buy |
| 2020-06-26 | Herabstufung | Goldman | Neutral → Sell |
| 2019-11-20 | Eingeleitet | Evercore ISI | Outperform |
| 2019-11-19 | Eingeleitet | Goldman | Neutral |
| 2019-11-19 | Eingeleitet | Jefferies | Buy |
| 2019-11-19 | Eingeleitet | Needham | Buy |
Alle ansehen
Phathom Pharmaceuticals Inc Aktie (PHAT) Neueste Nachrichten
Barclays Initiates Phathom Pharmaceuticals at Equalweight With $16 Price Target - marketscreener.com
Is WPIL Limited Still a Good Stock to Buy After Recent Earnings - earlytimes.in
Responsive Playbooks and the PHAT Inflection - news.stocktradersdaily.com
Phathom Pharmaceuticals stock hits 52-week high at 16.08 USD By Investing.com - Investing.com Nigeria
Is Phathom Pharmaceuticals Inc a good long term investmentIPO Market Watch & Budget Friendly Capital Growth - earlytimes.in
How Phathom Pharmaceuticals Inc. stock benefits from strong dollarJuly 2025 Earnings & Accurate Intraday Trading Signals - moha.gov.vn
Phathom Pharmaceuticals research links GLP-1 use to higher GERD risk - Traders Union
Phathom Pharmaceuticals Inc. (PHAT) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Phathom Pharmaceuticals: Superior Efficacy Drives Vonoprazan Growth (NASDAQ:PHAT) - Seeking Alpha
What Wall Street predicts for Phathom Pharmaceuticals Inc. stock priceJuly 2025 Macro Moves & Safe Entry Momentum Tips - newser.com
Is Phathom Pharmaceuticals Inc. stock a contrarian buyGap Up & Daily Growth Stock Tips - newser.com
Is Phathom Pharmaceuticals Inc. stock a smart buy before Fed meeting2025 Market Overview & Fast Moving Stock Trade Plans - newser.com
What margin trends mean for Phathom Pharmaceuticals Inc. stockJuly 2025 Summary & Daily Stock Momentum Reports - newser.com
Is Phathom Pharmaceuticals Inc. stock positioned for digital transformation2025 Market Sentiment & Safe Entry Trade Reports - newser.com
Understanding the Setup: (PHAT) and Scalable Risk - news.stocktradersdaily.com
Comparing Phathom Pharmaceuticals Inc. in custom built stock radarsJuly 2025 Momentum & AI Powered Buy and Sell Recommendations - newser.com
Volume spikes in Phathom Pharmaceuticals Inc. stock – what they meanMarket Risk Analysis & Growth Oriented Trade Recommendations - newser.com
Will Phathom Pharmaceuticals Inc. stock reach all time highs in 20252025 Top Decliners & Proven Capital Preservation Methods - newser.com
Volatility clustering patterns for Phathom Pharmaceuticals Inc.July 2025 Review & Capital Efficiency Focused Strategies - newser.com
Why Phathom Pharmaceuticals Inc. stock remains a top recommendationTrade Volume Summary & Stock Market Timing Techniques - newser.com
Is Phathom Pharmaceuticals Inc. stock a buy on dipsGlobal Markets & Community Shared Stock Ideas - newser.com
Can Phathom Pharmaceuticals Inc. recover in the next quarterJuly 2025 Update & Verified Momentum Stock Watchlist - newser.com
Strong Week for Phathom Pharmaceuticals (NASDAQ:PHAT) Shareholders Doesn't Alleviate Pain of Five-year Loss - 富途牛牛
How sentiment analysis helps forecast Phathom Pharmaceuticals Inc. - newser.com
Could Clinical Progress With VOQUEZNA Reshape Phathom Pharmaceuticals’ Long-Term Strategy (PHAT)? - Yahoo Finance
Finanzdaten der Phathom Pharmaceuticals Inc-Aktie (PHAT)
Umsatz
Nettogewinn
Free Cashflow
ENV
Phathom Pharmaceuticals Inc-Aktie (PHAT) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Breedlove Robert Charles | Principal Accounting Officer |
Nov 03 '25 |
Sale |
13.51 |
524 |
7,079 |
47,407 |
| Basta Steven L | President and CEO |
Sep 25 '25 |
Option Exercise |
0.00 |
90,000 |
0 |
90,000 |
| Breedlove Robert Charles | Principal Accounting Officer |
Sep 05 '25 |
Sale |
12.09 |
461 |
5,573 |
47,931 |
| Breedlove Robert Charles | Principal Accounting Officer |
Jul 16 '25 |
Sale |
8.36 |
1,692 |
14,152 |
48,392 |
| Topper James N | Director |
May 21 '25 |
Buy |
3.86 |
3,780 |
14,609 |
59,403 |
| Topper James N | Director |
May 14 '25 |
Buy |
3.32 |
6,300 |
20,919 |
55,623 |
| Topper James N | Director |
May 13 '25 |
Buy |
3.16 |
1,120 |
3,543 |
49,323 |
| Topper James N | Director |
May 09 '25 |
Buy |
3.22 |
35,602 |
114,616 |
35,602 |
| Topper James N | Director |
May 12 '25 |
Buy |
3.04 |
12,601 |
38,301 |
48,203 |
| Parikh Asit | Director |
May 06 '25 |
Buy |
2.60 |
5,000 |
13,000 |
90,500 |
1.12%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):